The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Celgene's 2013 oncology sales performance.
society alike – values which Celgene strive to achieve. ... Lisa McCurdy, Associate Director - Haematology, Celgene. “You never forget that feeling of being a winner and of knowing that you are at the very top of your profession – it means that
Celgene’s top psoriasis drug, Otezla (apremilast), which was raking in $1.6bn a year and growing fast, clashed with one of BMS' most promising molecules, deucravacitinib. ... As it became clear that anti-competition regulators would balk at BMS owning
The drug is part of a long-standing global collaboration with Celgene, now part of Bristol Myers Squibb (BMS).
The drug is part of a long-standing global collaboration with Celgene, now part of Bristol Myers Squibb (BMS).
The FDA approved Sarclisa for the treatment of patients with relapsed or refractor multiple myeloma who have received at least two prior therapies, including Celgene’s Revlimid (lenalidomide) and a proteasome
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...